Who makes Nanoformed Piroxicam IR Tablet?

Nanoformed Piroxicam IR Tablet is developed by Nanoform Finland Plc.

What development phase is Nanoformed Piroxicam IR Tablet in?

Nanoformed Piroxicam IR Tablet is in Phase 1.

Last reviewed 2026-05-13 · How we verify

Nanoformed Piroxicam IR Tablet

Nanoform Finland Plc · Phase 1 active Small molecule

At a glance

Generic name	Nanoformed Piroxicam IR Tablet
Also known as	Orally delivered Nanoformed Piroxicam IR tablet
Sponsor	Nanoform Finland Plc
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

PK Evaluation of a Nanoformed Oral IR Piroxicam Tablet in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Nanoformed Piroxicam IR Tablet CI brief — competitive landscape report
Nanoformed Piroxicam IR Tablet updates RSS · CI watch RSS
Nanoform Finland Plc portfolio CI